Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanjore S Balganesh

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Trends in Pharmacological Sciences|June 16, 2015
Exploring the potential of adjunct therapy in tuberculosisGeetha Vani Rayasam, Tanjore S Balganesh
Trends in Pharmacological Sciences|September 19, 2008
Rising standards for tuberculosis drug developmentTanjore S Balganesh, Pedro M Alzari, Stewart T Cole
Journal of Biomolecular Screening|February 1, 2013
Assay development for identifying inhibitors of the mycobacterial FadD32 activitySégolène Galandrin, Valérie Guillet, Rajendra S Rane, et al.
ACS Chemical Biology|December 28, 2012
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosisPravin S Shirude, Prashanti Madhavapeddi, Julie A Tucker, et al.
Chemmedchem|January 12, 2016
Nitroarenes as Antitubercular Agents: Stereoelectronic Modulation to Mitigate MutagenicitySudhir Landge, Vasanthi Ramachandran, Anupriya Kumar, et al.
Bioorganic & Medicinal Chemistry|December 9, 2015
Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidaseSudhir Landge, Amrita B Mullick, Kavitha Nagalapur, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Trends in Pharmacological Sciences|June 16, 2015
Exploring the potential of adjunct therapy in tuberculosisGeetha Vani Rayasam, Tanjore S Balganesh
Trends in Pharmacological Sciences|September 19, 2008
Rising standards for tuberculosis drug developmentTanjore S Balganesh, Pedro M Alzari, Stewart T Cole
Journal of Biomolecular Screening|February 1, 2013
Assay development for identifying inhibitors of the mycobacterial FadD32 activitySégolène Galandrin, Valérie Guillet, Rajendra S Rane, et al.
ACS Chemical Biology|December 28, 2012
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosisPravin S Shirude, Prashanti Madhavapeddi, Julie A Tucker, et al.
Chemmedchem|January 12, 2016
Nitroarenes as Antitubercular Agents: Stereoelectronic Modulation to Mitigate MutagenicitySudhir Landge, Vasanthi Ramachandran, Anupriya Kumar, et al.
Bioorganic & Medicinal Chemistry|December 9, 2015
Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidaseSudhir Landge, Amrita B Mullick, Kavitha Nagalapur, et al.
Pageof 1